www.fdanews.com/articles/142454-celator-pharmaceuticals-the-leukemia-amp-lymphoma-society-announce-positive-data-from-phase-iib-study-of-cpx-351
Celator Pharmaceuticals, the Leukemia & Lymphoma Society Announce Positive Data from Phase IIb Study of CPX-351
December 12, 2011
Celator Pharmaceuticals announced positive clinical data in first relapse patients with acute myeloid leukemia treated with CPX-351 (cytarabine:Daunorubicin) Liposome Injection.
MarketWatch
MarketWatch